SynthesisAnnals of surgical oncology2026
Prophylactic Intraperitoneal Chemotherapy with Platinum Agents Following Curative Resection for Colorectal Cancer: A Systematic Review and Meta-Analysis.
Synthesis in Annals of surgical oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Current Approaches and Emerging Strategies in the Treatment of Peritoneal Carcinomatosis.International journal of molecular sciences · 2026Review
- ASO Author Reflections: Clinical Promise of Platinum Prophylactic Intraperitoneal Chemotherapy in Colorectal Cancer.Annals of surgical oncology · 2026Article
- Does Prophylactic Intraperitoneal Chemotherapy Provide Any Clinical Benefit After Curative Colorectal Cancer Resection?Annals of surgical oncology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundPeritoneal recurrence is a significant concern after curative resection of colorectal cancer (CRC), with systemic chemotherapy providing limited prevention. Prophylactic intraperitoneal chemotherapy (PIC) using platinum-based agents offers a potential strategy to reduce recurrence and improve survival.
objectiveOur objective was to assess the effectiveness of platinum-based PIC in reducing peritoneal recurrence and enhancing survival outcomes when administered during or after curative CRC resection versus surgery alone or standard systemic therapy.
methodsWe conducted a systematic review and meta-analysis following Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA) 2020 guidelines. Databases were searched from January 2015 to September 2025 for randomized and comparative studies of adults receiving curative CRC resection with platinum-based PIC versus controls. Primary outcomes were overall survival (OS), disease-free survival (DFS), and peritoneal recurrence. Secondary outcomes were grade 3-4 adverse events and major complications. Random-effects meta-analyses in R used hazard ratios (HRs) for time-to-event outcomes and risk ratios (RRs) for binary outcomes; heterogeneity was assessed via I
resultsIn total, 16 studies were included in the qualitative synthesis and seven (three randomized controlled trials, four cohorts; n=1264) in the meta-analysis. Platinum-based PIC improved DFS (HR 0.57; 95% confidence interval [CI] 0.42-0.78, p=0.0004, I
conclusionsPlatinum-based PIC appears to enhance DFS without increasing adverse events or complications. Larger randomized controlled trials with longer follow-up are needed to confirm potential survival benefits and determine optimal protocols.
Indexed as
Identifiers
41402690What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.